A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Condition: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer Interventions: Drug: PF-06873600; Drug: Endocrine Therapy 1; Drug: Endocrine Therapy 2 Sponsor: Pfizer Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Fallopian Tube Cancer | HER2 | Male Breast Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Pfizer | Study